ArticleJournal of comparative effectiveness research2024

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting.

Alexander Russell-Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.